These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22207029)

  • 1. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
    Takahara T; Nitta H; Hasegawa Y; Itou N; Takahashi M; Nishizuka S; Wakabayashi G
    Cancer Chemother Pharmacol; 2012 May; 69(5):1127-33. PubMed ID: 22207029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
    Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
    World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
    Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
    Toyoda M; Ajiki T; Fujiwara Y; Nagano H; Kobayashi S; Sakai D; Hatano E; Kanai M; Nakamori S; Miyamoto A; Tsuji A; Kaihara S; Ikoma H; Takemura S; Toyokawa H; Terajima H; Morita S; Ioka T
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1295-301. PubMed ID: 24614947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Sakai D; Kodama Y; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2012 May; 69(5):1181-8. PubMed ID: 22237958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
    Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
    Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
    Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
    Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
    Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
    Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
    J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
    Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
    Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer.
    Moriwaki T; Ishida H; Araki M; Endo S; Yoshida S; Kobayashi M; Hamano Y; Sugaya A; Shimoyamada M; Hasegawa N; Imanishi M; Ito Y; Sato D; Hyodo I
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):669-74. PubMed ID: 25877225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
    J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.